The news was revealed by sources familiar with the acquisition. The source, who did not wish to be identified, stated to the media that in order to acquire a 30% stake in Samsung Biopharmaceuticals, the funds raised for Samsung's consideration are 3 trillion won (approximately 28%). One hundred million U.S. dollars).
The source also revealed that Samsung’s products are currently in contact with major financial institutions on fundraising matters.
Samsung Biopharmaceuticals, which plans to acquire a 30% stake in Samsung, was established in 2012. Currently, five biopharmaceuticals have been approved by Europe and one biopharmaceutical has been approved in the United States.
In terms of equity, Samsung's 94.6% stake in Samsung Biopharm is owned by Samsung Biopharmaceuticals, while the remaining 5.4% is owned by biogen giant Biogen, but Biogen can increase its stake in Samsung Biopharmaceuticals to 49.9%.